Word

EXOTAC

Status

Registered

Status Code

700

Status Date

Tuesday, July 30, 2024

Serial Number

97106183

Registration Number

7459469

Registration Date

Tuesday, July 30, 2024

Mark Type

4

Filing Date

Wednesday, November 3, 2021

Published for Opposition

Tuesday, May 14, 2024

Trademark Owner History

ILIAS Biologics Inc. - Original Registrant

Classifications

5 Biological preparations for medical or veterinary purposes for the treatment of cancer, metabolic diseases, inflammatory diseases, genetic diseases, infectious diseases, cardiovascular diseases, respiratory diseases, neurological diseases, auto-immune diseases, fibrosis diseases, allergies, skin diseases, endocrine diseases, gastrointestinal diseases, hematologic diseases, diseases and disorders of the immune system, ophthalmic diseases, kidney diseases, and urinary diseases; biochemical preparations for medical or veterinary purposes for the treatment of cancer, metabolic diseases, inflammatory diseases, genetic diseases, infectious diseases, cardiovascular diseases, respiratory diseases, neurological diseases, auto-immune diseases, fibrosis diseases, allergies, skin diseases, endocrine diseases, gastrointestinal diseases, hematologic diseases, diseases and disorders of the immune system, ophthalmic diseases, kidney diseases, and urinary diseases; drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; pharmaceuticals featuring drug delivery system, namely, pharmaceutical preparations for the treatment of cancer, metabolic diseases, inflammatory diseases, genetic diseases, infectious diseases, cardiovascular diseases, respiratory diseases, neurological diseases, auto-immune diseases, fibrosis diseases, allergies, skin diseases, endocrine diseases, gastrointestinal diseases, hematologic diseases, diseases and disorders of the immune system, ophthalmic diseases, kidney diseases, urinary diseases; preparations for intracellular drug delivery, namely, drug delivery agents in the form of capsules, tablets, pills, powders, liquids, suspensions, injections, creams, emulsions, gels, liniments, lotions, ointments, pathes, solutions, syrups, aerosols, granules, implants, inhalants, pellets that facilitate the delivery of pharmaceutical preparations; pharmaceuticals for the treatment of immune system disease; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the treatment of inflammatory diseases; pharmaceutical preparations for the treatment of immune system related diseases and disorders; pharmaceutical preparations for the treatment of cellular diseases; chemico-pharmaceutical preparations for the treatment of cancer, metabolic diseases, inflammatory diseases, genetic diseases, infectious diseases, cardiovascular diseases, respiratory diseases, neurological diseases, auto-immune diseases, fibrosis diseases, allergies, skin diseases, endocrine diseases, gastrointestinal diseases, hematologic diseases, diseases and disorders of the immune system, ophthalmic diseases, kidney diseases, and urinary diseases; protein preparations, namely, protein supplements; biotechnological preparations for medical purposes for treatment of cancer, metabolic diseases, inflammatory diseases, genetic diseases, infectious diseases, cardiovascular diseases, respiratory diseases, neurological diseases, auto-immune diseases, fibrosis diseases, allergies, skin diseases, endocrine diseases, gastrointestinal diseases, hematologic diseases, diseases and disorders of the immune system, ophthalmic diseases, kidney diseases, and urinary diseases; reagents for medical use; pharmaceuticals for human purposes for the treatment of cancer, metabolic diseases, inflammatory diseases, genetic diseases, infectious diseases, cardiovascular diseases, respiratory diseases, neurological diseases, auto-immune diseases, fibrosis diseases, allergies, skin diseases, endocrine diseases, gastrointestinal diseases, hematologic diseases, diseases and disorders of the immune system, ophthalmic diseases, kidney diseases, and urinary diseases; biochemical pharmaceuticals for the treatment of cancer, metabolic diseases, inflammatory diseases, genetic diseases, infectious diseases, cardiovascular diseases, respiratory diseases, neurological diseases, auto-immune diseases, fibrosis diseases, allergies, skin diseases, endocrine diseases, gastrointestinal diseases, hematologic diseases, diseases and disorders of the immune system, ophthalmic diseases, kidney diseases, and urinary diseases; biological tissue cultures for medical purposes; diagnostic reagents for medical use; pharmaceuticals for the treatment of cancer, metabolic diseases, inflammatory diseases, genetic diseases, infectious diseases, cardiovascular diseases, respiratory diseases, neurological diseases, auto-immune diseases, fibrosis diseases, allergies, skin diseases, endocrine diseases, gastrointestinal diseases, hematologic diseases, diseases and disorders of the immune system, ophthalmic diseases, kidney diseases, and urinary diseases

1 Biological preparations, other than for medical or veterinary purposes; biological preparation for use in cell cultures other than for medical or veterinary use; biological preparation for use in the manufacture of pharmaceuticals; biological preparations for use in experiments containing exosomes carrying the desired protein, other than for medical or veterinary use; biochemical preparations for gene recombination for scientific or laboratory purposes; biological tissue cultures, other than for medical or veterinary purposes; cells for scientific or laboratory purposes; biological preparations for scientific or laboratory purposes other than for medical or veterinary use; diagnostic reagents for scientific or research use; diagnostic reagents for use in biological or genetic engineering for scientific or research use and medical laboratory use; reagents for scientific or medical research use; biological preparations for use in biotechnology industry and science, other than for medical purpose; cell growth media for growing cells for use in scientific research; biochemicals for in vitro and in vivo scientific use; reagents for medical research; biological preparation containingexosomes for use in manufacture of cosmetics; protein for use in the manufacture of cosmetics; chemical preparations for use in the manufacture of cosmetics; chemical additives for use in the manufacture of cosmetics; proteins for the food industry

42 Research and development of technology for biotechnology; development of pharmaceutical preparations and medicines; development of cell therapy products; research and development of new pharmaceuticals; medical research and product development services; research and development of vaccines and medicines; product development in the field of biologics; research of biologics, namely, scientific study and research in the field of biologics; laboratory research in the field of biology; industrial research in the field of biomedical engineering; technological research in the field of cell biology; scientific research in the field of pharmaceuticals; biotechnology research; biological research services; research for medical products; research in the field of chemistry; drug discovery services; biomedical research services; pharmaceutical drug development services

Trademark Events

Nov 6, 2021

New Application Entered

Nov 13, 2021

New Application Office Supplied Data Entered

Aug 13, 2022

Assigned To Examiner

Aug 21, 2022

Non-Final Action Written

Aug 21, 2022

Non-Final Action E-Mailed

Aug 21, 2022

Notification Of Non-Final Action E-Mailed

Feb 18, 2023

Teas Response To Office Action Received

Feb 18, 2023

Correspondence Received In Law Office

Feb 20, 2023

Teas/Email Correspondence Entered

Mar 14, 2023

Suspension Letter Written

Mar 14, 2023

Letter Of Suspension E-Mailed

Mar 14, 2023

Notification Of Letter Of Suspension E-Mailed

Sep 11, 2023

Suspension Inquiry Written

Sep 11, 2023

Inquiry To Suspension E-Mailed

Sep 11, 2023

Notification Of Inquiry As To Suspension E-Mailed

Nov 18, 2023

Teas Response To Suspension Inquiry Received

Apr 9, 2024

Assigned To Lie

Apr 11, 2024

Correspondence Received In Law Office

Apr 11, 2024

Teas/Email Correspondence Entered

Apr 11, 2024

Approved For Pub - Principal Register

Apr 24, 2024

Notification Of Notice Of Publication E-Mailed

May 14, 2024

Published For Opposition

May 14, 2024

Official Gazette Publication Confirmation E-Mailed

Jul 30, 2024

Registered-Principal Register

Jul 30, 2024

Notice Of Registration Confirmation Emailed